Result of AGM and Appointment of Joint Broker

30 June 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Result of AGM and Appointment of Joint Broker

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. Details of the votes received will be available shortly on the Company's website.

As announced on 7 June 2022, Kevin Alexander has ceased to be a director of the Company following the conclusion of the AGM.

Appointment of Joint Broker

Further to the announcement made today in relation to the Company's fundraise, the Company is pleased to announce the appointment of Turner Pope Investments (TPI) Limited as joint broker to the Company with immediate effect.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc   Dr Suzanne Dilly, CEO	Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)   Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: +44 (0) 20 7213 088
Cenkos Securities Limited (Joint Broker)   Russell Kerr/Michael Johnson (Sales)   Callum Davidson/Giles Balleny (Corporate Finance)	Tel: +44 (0) 20 7397 8900
Turner Pope Investments (TPI) Limited  (Joint Broker)   James Pope / Andy Thacker	Tel: +44 (0) 20 3657 0050

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.   https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.